S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
Ship heads to Ukraine to get grain for food-starved Africa
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
NASDAQ:FIXX

Homology Medicines - FIXX Price Target & Analyst Ratings

$2.76
-0.09 (-3.16%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.60
$2.93
50-Day Range
$1.78
$2.97
52-Week Range
$1.30
$8.90
Volume
129,899 shs
Average Volume
193,704 shs
Market Capitalization
$158.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.01

Homology Medicines Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$13.01
371.42% Upside
High Prediction$29.00
Average Prediction$13.01
Low Prediction$3.10
TypeCurrent
8/13/21 to 8/13/22
1 Month Ago
7/14/21 to 7/14/22
3 Months Ago
5/15/21 to 5/15/22
1 Year Ago
8/13/20 to 8/13/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.01$13.01$14.38$22.67
Predicted Upside371.42% Upside334.09% Upside301.80% Upside116.82% Upside
Get Homology Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.


FIXX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FIXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Homology Medicines Stock vs. The Competition

TypeHomology MedicinesMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside371.42% Upside722.97% Upside13.81% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
118
64.84%
Underperform Votes
64
35.16%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/20/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$3.10+73.18%
5/23/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$20.00+1,177.95%
5/17/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNA$14.00+852.38%
4/6/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$19.00 ➝ $7.00+143.06%
4/6/2022FIX
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$19.00 ➝ $7.00+143.06%
2/22/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $9.00+219.15%
2/22/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$35.00 ➝ $29.00+651.29%
2/22/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luca Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$30.00 ➝ $4.00+3.63%
2/22/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Biegler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/1/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$14.00+24.33%
3/13/2020Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$30.00 ➝ $32.00+125.83%
(Data available from 8/13/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












FIXX Price Target - Frequently Asked Questions

What is Homology Medicines's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Homology Medicines stock is Hold based on the current 4 hold ratings and 4 buy ratings for FIXX. The average twelve-month price prediction for Homology Medicines is $13.01 with a high price target of $29.00 and a low price target of $3.10. Learn more on FIXX's analyst rating history.

Do Wall Street analysts like Homology Medicines more than its competitors?

Analysts like Homology Medicines less than other Medical companies. The consensus rating for Homology Medicines is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how FIXX compares to other companies.

Do MarketBeat users like Homology Medicines more than its competitors?

MarketBeat users like Homology Medicines less than other Medical companies. 64.84% of MarketBeat users gave Homology Medicines an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Homology Medicines's stock price have much upside?

According to analysts, Homology Medicines's stock has a predicted upside of 334.09% based on their 12-month price targets.

What analysts cover Homology Medicines?

Homology Medicines has been rated by Chardan Capital, Credit Suisse Group, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:FIXX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.